About Caladrius

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease.

Recent News

May 12, 2021
Caladrius Biosciences Receives $1.4 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program

May 6, 2021
Caladrius Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update

May 4, 2021
Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in May 2021

Events

May 6, 2021
Caladrius Biosciences 1st Quarter 2021 Financial Results and Business Update Conference Call

February 25, 2021
Fourth Quarter and Year End 2020 Financial Results Conference Call

January 19, 2021
NobleCon17: Noble Capital Markets’ Seventeenth Annual Investor / Equity Conference (Virtual)

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

NobleCon17: Noble Capital Markets’ Seventeenth Annual Investor / Equity Conference (Virtual)

CD34+ Cell Technology